1. What was the background and rationale behind the phase 1 study investigating M7824 in biliary tract cancer? (0:11)
2. What were the preliminary findings from the study? (1:16)
3. What are the most promising areas and next steps in this area of research over the coming years? (2:20)
4. What developments are you most excited about in this area over the next few years? (3:11)
Speaker disclosures: Do-Youn Oh has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.